# Comparison of Two Formulations of Proellex for Oral Administration

> **NCT02141061** · PHASE1 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telapristone Acetate, Proellex 12 mg Formulation A
- **DRUG:** Telapristone Acetate, Proellex 12 mg Formulation B

## Key facts

- **NCT ID:** NCT02141061
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141061, "Comparison of Two Formulations of Proellex for Oral Administration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02141061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*